Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Theranostics Market Expansion From $136.02 Billion In 2026 To $205.53 Billion In 2030

In the domain of theranostics, a notable surge in market valuation has been observed lately. Projections indicate sustained expansion, escalating from 122.98 billion dollars in 2025 to 136.02 billion dollars by 2026, reflecting a compound annual growth rate of 10.6%. Key factors contributing to this upward trend during the preceding period include sophisticated developments in molecular diagnostic techniques, a rising incidence of long-term health conditions, heightened investment in cancer research initiatives, the introduction of precisely targeted treatments, and the broader availability of diagnostic laboratory facilities.

The theranostics sector is poised for substantial expansion in the upcoming years, projecting a market value of $205.54 billion by 2030, fueled by a compound annual growth rate of 10.9%. This projected increase is largely driven by escalating investments in precision medicine, the increasing utilization of artificial intelligence in diagnostic technologies, the broadening scope of theranostic applications within oncology, the growing incorporation of genomic data into medical decision-making, and a heightened demand for tailored therapeutic results. Key developments during this projection period are anticipated to include a closer alignment between diagnostic processes and targeted treatments, a greater embrace of personalized medicine frameworks, expanded use of molecular imaging methodologies, a surge in the development of companion diagnostics, and a more concentrated emphasis on individualized patient treatment strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

Theranostics Market Growth Momentum: Which Factors Are Influencing Demand?

The escalating incidence of cancer is poised to be a significant catalyst for the expansion of the theranostics market. Cancer, characterized by aberrant cellular proliferation that affects numerous organs and results in considerable illness and fatalities globally, stands to benefit from theranostics. This innovative methodology, which synergistically combines therapeutic and diagnostic elements, holds substantial promise for managing cancer and other persistent health conditions. By merging diagnostic acuity with therapeutic intervention, theranostics facilitates tailored and precise treatment strategies, thereby fostering avenues for advancements within the healthcare sector. Consequently, an increasing patient population afflicted with cancer is anticipated to fuel the expansion of the theranostics marketplace. As an illustration, in August 2024, Macmillan Cancer Support, an entity based in the United Kingdom, revealed that in 2024, upwards of 3 million individuals in the UK were contending with cancer, a number expected to reach 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the growing burden of cancer is directly contributing to the advancement of the theranostics industry.

Theranostics Market Segmentation And Category Breakdown

The theranostics market covered in this report is segmented –

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases

2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Neurological Disorders: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy

2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension

3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis

4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders

Theranostics Market Trends Reshaping Industry Growth

Key players within the theranostics sector are concentrating their efforts on creating sophisticated offerings, including theranostics clinical studies, with the objective of advancing personalized care and optimizing patient results through the unified application of diagnostic and therapeutic interventions. These theranostic clinical trials serve as investigations designed to assess the efficacy of concurrently deploying diagnostic tools and precision-driven treatments for the purpose of customizing therapeutic plans on an individual patient basis. The underlying goal of these evaluations is to ascertain the success of particular interventions predicated on patient-unique biomarkers, consequently refining the landscape of personalized medicine. As an illustration, in May of 2024, BAMF Health, an American oncology facility, initiated the COMBAT Trial, formally designated “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Notable characteristics of this trial include an accelerated initiation timeline facilitated by BAMF Health’s BAMF RapAct initiative, enabling its commencement in a mere seven weeks, alongside a strategic emphasis on employing novel radiopharmaceuticals targeted at the Gastrin-Releasing Peptide receptor (GRPR), which is intended to expand therapeutic alternatives for individuals facing restricted treatment possibilities.

Theranostics Market Competitive Analysis Of Major Industry Participants

Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Access The Complete Theranostics Market Report:

https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Theranostics Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the global theranostics market in 2025.Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model